Pyxis Oncology, Inc. is reallocating its resources to focus on the development of its leading asset, PYX-201, a pioneering antibody-drug conjugate (ADC) showing promising efficacy in treating head and ...

BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs ...

Allakos Inc. announced that its phase 1 trial of AK006 for chronic spontaneous urticaria (CSU) did not show therapeutic efficacy, leading the company to discontinue its development. While AK006 was ...

China's 6G research and development has completed the first phase of technical trials, forming a reserve of more than 300 key ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

GlyphAgo is an oral prodrug of agomelatine, a medicine with established clinical efficacy in four out of four previous third-party randomized, placebo-controlled studies in generalized anxiety ...

Iris 2 partners (left to right): Adel al Saleh, CEO of SES; Timo Personen, European Commission director-general for defense industry and space; Eva Berneke, CEO of Eutelsat Group; Andrius Kublius, ...

The Galaxy at Polaris mixed-use development is now open at 8770 Galaxy Way. John Bush, Columbus Business First To continue reading this content, please enable ...

Work is set to begin on the final phase of Jeffrey Park, more than four decades and 1,600 homes after the Columbus development helped launch the revival of Italian Village. The developer, ...

A Zionsville-based developer is preparing for the next phase of development at a 48-acre residential and commercial project along Michigan Road in Zionsville. Pittman Partners plans to build up to 225 ...